Objective-To determine the efficacy and dose requirements of captopril to reduce functional mitral regurgitation in patients with dilated heart failure. Design-A randomised double blind placebo controlled parallel arm trial. Incremental daily doses of 25 mg, 50 mg and 100 mg captopril used for a four week period each for a total of 12 weeks preceded by a two week placebo washout. Twenty eight ambulatory patients (mean age 72) New York Heart Association (NYHA) class H or III with apparently controlled ischaemic dilated heart failure (ejection fraction 29% (0-04%)) on digoxin, diuretics, and nitrates were randomised. All had at least grade 214 functional mitral regurgitation (>5 cm2 regurgitant area on colour flow Doppler). Results-Twenty three patients completed the study (13 on placebo and 10 on captopril). Significant improvements were confined to the captopril group. Compared with placebo the following improvements were noted in the captopril treated group: mitral regurgitant area decreased from a threshold at 50 mglday (p < 005, mean (95% confidence interval (95% CI)) 3*1 (0.2 to 6.0) cm2), with a fiuther decrease at 100 mg/day (p < 0-01, mean (95% CI) 5-3 (3-1 to 7-5) cm2). Significant improvements in all the other measurements were noted only after 100 mglday. Stroke Functional mitral regurgitation is a consistent finding in dilated heart failure' leading to a vicious cycle of ventricular and atrial overload, increase in pulmonary wedge pressure,2 and congestive symptoms. Load reduction with vasodilators redirects mitral regurgitation forward both at rest3 and after exercise4 thereby increasing cardiac output, improving ventricular and atrial geometry with a further decrease in mitral regurgitation. This results in sustained improvement in symptoms. Although the acute haemodynamic effects of the angiotensin converting enzyme (ACE) inhibitor captopril are known,' its ability to reduce functional mitral regurgitation in dilated heart failure has not been investigated in a placebo controlled study. Moreover the optimal dose of captopril for dilated heart failure is unknown and there is a tendency among both British and North American prescribers to use subtherapeutic doses especially in elderly patients for fear of side effects.67 Recent evidence suggests that low dose compared with high dose ACE inhibitor treatment is associated with higher mortality.8 In our heart failure data bank of 233 cases enrolled over the past two years the overall prevalence of functional mitral regurgitation was 51%, with 37% having functional mitral regurgitant jets >5cm2 on colour flow Doppler (regurgitant grade 2/4 or higher). Yet overall only 9-4% were on high dose ACE inhibitor treatment (>50 mg captopril/day or >10 mg enalapril/day); most were on lower doses. Residual mitral regurgitation may reflect ineffective or inadequate treatment.
Incremental daily doses of 25 mg, 50 mg and 100 mg captopril used for a four week period each for a total of 12 weeks preceded by a two week placebo washout. Twenty eight ambulatory patients (mean age 72) New York Heart Association (NYHA) class H or III with apparently controlled ischaemic dilated heart failure (ejection fraction 29% (0-04%)) on digoxin, diuretics, and nitrates were randomised. All had at least grade 214 functional mitral regurgitation (>5 cm2 regurgitant area on colour flow Doppler). Results-Twenty three patients completed the study (13 on placebo and 10 on captopril). Significant improvements were confined to the captopril group. Compared with placebo the following improvements were noted in the captopril treated group: mitral regurgitant area decreased from a threshold at 50 mglday (p < 005, mean (95% confidence interval (95% CI)) 3*1 (0.2 to 6.0) cm2), with a fiuther decrease at 100 mg/day (p < 0-01, mean (95% CI) 5-3 (3-1 to cm2). Significant improvements in all the other measurements were noted only after 100 mglday. Stroke volume increased (p < 0-01, mean (95% CI) 11, (1.4 to 21) ml), systemic vascular resistance decreased (p < 0*05, mean (95% CI) 414 (35 to 793) dyn s cm5), left atrial area decreased (p < 0-05, mean (95% CI) 4.3 (0.03 to 8.6) cm7), and deceleration time increased (p < 0'01, mean (95% CI) 52 ms (7 to 98) ms). Left ventricular diameter decreased marginally (p = 0-06, mean (95% CI) 4 (-0.05 to 9 mm). Duke activity index score increased (p < 0O001, median (95% CI) [6] [7] [8] (4.5 Functional mitral regurgitation is a consistent finding in dilated heart failure' leading to a vicious cycle of ventricular and atrial overload, increase in pulmonary wedge pressure,2 and congestive symptoms. Load reduction with vasodilators redirects mitral regurgitation forward both at rest3 and after exercise4 thereby increasing cardiac output, improving ventricular and atrial geometry with a further decrease in mitral regurgitation. This results in sustained improvement in symptoms. Although the acute haemodynamic effects of the angiotensin converting enzyme (ACE) inhibitor captopril are known,' its ability to reduce functional mitral regurgitation in dilated heart failure has not been investigated in a placebo controlled study. Moreover the optimal dose of captopril for dilated heart failure is unknown and there is a tendency among both British and North American prescribers to use subtherapeutic doses especially in elderly patients for fear of side effects.67 Recent evidence suggests that low dose compared with high dose ACE inhibitor treatment is associated with higher mortality.8 In our heart failure data bank of 233 cases enrolled over the past two years the overall prevalence of functional mitral regurgitation was 51%, with 37% having functional mitral regurgitant jets >5cm2 on colour flow Doppler (regurgitant grade 2/4 or higher). Yet was assessed from the apical four chamber view by measuring the maximal area of the regurgitant jet on colour flow Doppler,'2 which included the aliasing and non-aliasing jet areas. Equipment settings that included the colour variance maps, frame rate, and depth were kept constant for each patient but gain was optimised to a level just below the point of appearance of noise artefact. Left atrial area was measured with planimetry from the frozen apical four chamber view at end systole. The left ventricular diastolic filling was assessed by sampling transmitral flow at the tip of the mitral valve from an apical four chamber view."3 Special emphasis was made on the deceleration time of the early filling (E) wave. A shortened deceleration time is known to be associated with raised filling pressures and high diastolic pressures.'4 15 The Duke activity status index'6 has been shown to have a reasonable correlation with maximum oxygen consumption at peak exercise and is a good measure of functional capacity. It ranges from a minimum score of 2-75 points for activities of daily living (independence in dressing and bathing) to a cumulative total of 58-2 points for one who is playing strenuous sports. This was assessed at randomisation and at the end of the 12 week study.
WITCHIN OBSERVER VARIABILITY One investigator, who was blinded, assessed the clinical state and performed all the Doppler echocardiographic studies. Readings were averaged over three cycles for patients in sinus rhythm and over five cardiac cycles for the five patients in atrial fibrillation. The variability of left ventricular stroke volume was assessed at 3 1% (0-5 ml). Within observer variability for mitral regurgitant area was 6% (0-1 cm2). Day to day variation in mitral regurgitation in dilated cardiomyopathy is known to be about 15% (NS).17 Hence a >30% reduction in jet area would be needed to predict a therapeutic response at the level of the 95% confidence interval (95% CI). Twenty two patients completing the study would enable an adequate analysis at the level p < 0 05 with 80% power.
Effect ofcaptwprd on functional mitral regurgitation in dilated heartfailure: a randomised double blind placebo controlled trial Table 2 and figure 1 show that mitral regurgitant area did not decrease significantly in the placebo group (F = 1-26; p = 0-29) whereas a significant decrease, compared with both baseline and placebo, was found in the captopril group (F = 9-87; p < 0-001). Compared with placebo captopril decreased mitral regurgitation from a threshold dose of 50 mg/day (p < 0 05; mean (95% CI) 3d1 (0-2 to 6) cm2) with a further decrease at 100 mg/day (p < 0-01; mean (95% CI) 5 figure 2 show that stroke volume did not increase significantly in the control group (F = 1-92; p = 0-01) but a significant increase was noted at a threshold of 100 mg of captopril daily (F = 3-64; p < 0 02).
Differences in favour of captopril compared with placebo were noted only after doses of 100 mg/day (p < 0-01; mean (95% CI) 11 (1-4 to 21)ml). Table 2 and figure 5 show that the deceleration time of the E wave did not increase after placebo (F = 0-39; p = 0-7). Significant differences in favour of captopril were seen, marginally after 50 mg/day and maximally at the 100 mg daily dose (p < 0 01; mean (95% CI) 52 (7 to 98) ms). figure 6 show that the Duke activity index score increased by a (median 95% CI) of 6&8(4-5 to 12) points after 100 mg/day of captopril whereas there was no improvement with placebo (Mann-Whitney U test; p < 0.001).
Heart rate, systolic blood pressure, mean arterial pressure, serum creatinine, and serum potassium concentrations did not change with either placebo or captopril. Three patients in the placebo group required an increase in diuretic dose to control weight gain. Of the five patients who had their low dose ACE inhibitors withdrawn, three were randomised to placebo and none deteriorated clinically or haemodynamically during the 12 Deceleration time increased (p < 0'03; mean (95% CI) 32 (4 to 61)ms). Systemic vascular resistance decreased (p < 0 09; mean (95% CI) 522 (175-870) dyn.s.cm-5). Duke activity increased (p < 0-01; mean (95% CI) 4-5 (0-9-8<1) points). The mean arterial pressure, heart rate, systolic blood pressure, left atrial area, and left ventricular end diastolic diameter did not change significantly. These findings are comparable with those obtained on 100 mg/day at the end of 12 weeks with the exception of the left atrial area.
Discussion
Our study shows that captopril is efficacious in reducing functional mitral regurgitation in patients with dilated heart failure (with NYHA class II or III symptoms), but a dose of at least 50-100 mg/day is required to show significant additive effects over supervised conventional treatment. These doses, reached by gradual increments, were safe and well tolerated even in an elderly population and there was no reduction in renal function or mean arterial blood pressure. As noted in previous studies the placebo group showed an improvement in some haemodynamics although this was not significant. This improvement may reflect the intense supervision of the cardiac nurse in ensuring drug compliance. Captopril reduced mitral regurgitant area by 50% after 50 mg/day and by 77% after 100 mg/day whereas placebo caused only a maximum reduction of 21%, which was not significant. Reduction of mitral regurgitation would reduce left ventricular and left atrial loading with decreased left atrial size and decreased left ventricular filling and wedge pressures. A significant reduction in left atrial size was seen after the 100 mg daily dose. A smaller left atrial size resulting from the decrease in size of the atrioventricular orifice would decrease mitral regurgitation further and may prevent or delay the onset of atrial fibrillation. A decrease in left ventricular filling and end diastolic pressure was reflected by a significant lengthening of the deceleration time of the early filling Doppler (E) wave. This signals an easing of the restrictive physiology seen with high filling pressures.'415 At least 100 mg/day was needed to show significant increases in stroke volume and reduction in systemic vascular resistance. The Duke activity status index score improved by an average of 6-9 points with captopril at the end of 12 weeks whereas there was no improvement with placebo (p < 0-001). This could be translated to an improvement in a patient who was once limited to light work in the house being able to do moderate work, such as carrying groceries and working in the garden.
Left ventricular diameter decreased with captopril but this did not reach significance (p = 0-06). Previous work has shown a reduction in left ventricular volume after reduction in mitral regurgitation with vasodilator treatment.' Measurement by M mode would be too insensitive to show changes in left ventricular volume. Recently the studies of left ventricular dysfunction (SOLVD) group showed by ventriculography that long-term enalapril treatment resulted in a sustained reduction in left ventricular volume whereas there were progressive increases in left ventricular volume in the placebo treated group.'8 The mechanism of this effect was not clear. It is tempting to postulate that, among other effects, ACE inhibitor treatment may have reduced the functional mitral regurgitation common in NYHA class II and III heart failure.
The presence of finctional mitral regurgitation in congestive heart failure is, we believe, a marker of clinical importance. It identifies a group of patients most likely to benefit from vasodilator treatment. '9 In patients, as our study group, already on conventional treatment or taking low dose ACE inhibitors its presence indicates inadequacy of treatment for load reduction. Based on the premise that vasodilators redirect regurgitant flow to increase forward stroke volume, increasing the dose of vasodilators would lead to increased cardiac output without a drop in mean arterial pressure, as was found in our study. Patients with dilated heart failure do not necessarily require high filling pressures to maintain cardiac output; they could function well at normal filing pressures.20 Hence aggressive treatment is both safe and warranted.
Although the acute haemodynamic effects of captopril are independent of dose (12-5-100 mg) they do not predict the longterm response.2' A sustained effect depends on a relatively high dose that is the cornerstone of chronic treatment.22 Exercise capacity improves gradually over four to six weeks after fixed doses of captopril. To make allowances for this time effect each dose period was four weeks in our study. Hence the haemodynamic changes at the end of four weeks would be a valid reflection of the effects of the respective doses. There was no improvement in any of the measurements at the fourth week (25 mg/day) and even after eight weeks (50 mg/day) improvements in mitral regurgitation and deceleration time were only just perceptible. Yet in the open phase trial significant improvements were noted in four weeks (100 mg/day) comparable with those seen at 12 weeks in the graded study. Of three patients who had their low dose ACE inhibitors withdrawn and who were randomised to placebo, none deteriorated clinically or haemodynamically after 12 weeks. Although this is not absolute proof, these data support the importance of dose overriding time, but it is still conceivable that the lower dose (50 mg/day) given over a longer period than 
